Ligand Pharmaceuticals (LGND) Cash & Equivalents Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.29% |
| Dec 31, 2025 | 29.72% |
| Sep 30, 2025 | -21.14% |
| Jun 30, 2025 | -10.09% |
| Mar 31, 2025 | -16.40% |
| Dec 31, 2024 | 0.21% |
| Sep 30, 2024 | -22.35% |
| Jun 30, 2024 | -41.86% |
| Mar 31, 2024 | -13.78% |
| Dec 31, 2023 | -27.82% |
| Sep 30, 2023 | -30.11% |
| Jun 30, 2023 | -28.43% |
| Mar 31, 2023 | 11.70% |
| Dec 31, 2022 | 37.07% |
| Sep 30, 2022 | -33.95% |
| Jun 30, 2022 | -38.54% |
| Mar 31, 2022 | 7.10% |
| Dec 31, 2021 | 0.81% |
| Sep 30, 2021 | -23.00% |
| Jun 30, 2021 | -18.65% |
| Mar 31, 2021 | 0.36% |
| Dec 31, 2020 | -13.34% |
| Sep 30, 2020 | 37.26% |
| Jun 30, 2020 | 1.25% |
| Mar 31, 2020 | -6.65% |
| Dec 31, 2019 | -14.89% |
| Sep 30, 2019 | 4.52% |
| Jun 30, 2019 | 79.79% |
| Mar 31, 2019 | 51.95% |
| Dec 31, 2018 | 58.70% |
| Sep 30, 2018 | 104.00% |
| Jun 30, 2018 | 91.23% |
| Mar 31, 2018 | 58.90% |
| Dec 31, 2017 | -5.56% |
| Sep 30, 2017 | 35.96% |
| Jun 30, 2017 | 46.63% |
| Mar 31, 2017 | 1.71% |
| Dec 31, 2016 | 21.64% |
| Sep 30, 2016 | 107.50% |
| Jun 30, 2016 | 77.92% |
| Mar 31, 2016 | 38.99% |
| Dec 31, 2015 | 96.26% |
| Sep 30, 2015 | 89.91% |
| Jun 30, 2015 | 101.79% |